Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer

N/ATerminatedNCT02040493

Xoft, Inc.75 enrolled

Overview

This is a physician sponsored multi-center, non-randomized, prospectively enrolling data collection study of patients with early stage breast cancer treated with electronic brachytherapy at the time of surgical resection of the cancer in the operating room. The radiation therapy treatments will be administered with electronic brachytherapy using the FDA cleared Xoft Axxent System.

Breast Conserving Therapy (BCT) is a standard treatment option for patients with stage I or II breast cancer. Breast conserving therapy consists of surgical removal of the tumor with negative margins, axillary lymph node dissection or sentinel node biopsy and radiation therapy. Several studies have shown BCT to be comparable to mastectomy in terms of overall and disease free survival for patients. The major advantage to BCT over mastectomy is breast preservation and reduced psychological trauma to the patient. The major disadvantage to BCT is prolonged time of treatment. The whole breast radiation portion of BCT can add 7 weeks to the treatment time. This additional treatment time can be a detriment to women who logistically may not be able to meet the demands of daily irradiation for 6-7 weeks. A new form of treatment, breast brachytherapy, was developed to decrease the treatment time required for breast irradiation. This treatment uses the Xoft Axxent system to administer intra-operative breast brachytherapy in one treatment, at the time of lumpectomy in the operating room. This study has been designed to assess local recurrence, serious adverse events, adverse events and their severity, and cosmesis following intra-operative radiation therapy (IORT) using the Xoft Axxent System and balloon applicators. The study device is FDA cleared. The purpose of this clinical study is to compile data on the treatment of patients using the Xoft Axxent System for the delivery of radiation therapy in the intra-operative setting as part of breast conserving therapy in women with resected, early stage breast cancer.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Breast Cancer

Interventions

Intra-operative radiation therapy (IORT)RADIATION

All subjects will receive IORT at the time of lumpectomy.

Eligibility

Sex: FEMALEMin age: 45 Years

Medical Language ↔ Plain English

General Inclusion Criteria 1. Age \> 45 years 2. Tumor with Tis, T1, T2 (≤ 3cm), N0, M0 - (AJC Classification) 3. Invasive ductal carcinoma and / or DCIS Intra-operative Inclusion Criteria 1. Negative sentinel node assessment 2. Balloon surface to skin distance of at least 1-cm and adequate conformance via Intra-operative ultrasound Post procedure Inclusion Criteria 1. Negative microscopic surgical margins\*\* \*\*If positive margins patient my undergo re-excision and/or additional radiation at the treating physician's discretion but the patient will be excluded from the protocol data analysis. General Exclusion Criteria 1. Scleroderma, systemic sclerosis and active lupus 2. Participation in an investigational drug or device study 3. Previous ipsilateral radiation to the thorax or breast Intra-operative Exclusion Criteria 1. Intra-operative positive sentinel lymph node biopsy 2. Inadequate conformance (greater than 10% of PTV encompassed by fluid or air on physician assessment of intraOp ultrasound image) 3. Skin spacing less than 1-cm via intraOp ultrasound. 4. A cavity size that is not appropriate for a 40 -70 cc balloon. 5. Patient becomes unstable and physician determines patient is not a good candidate at time of lumpectomy.

Locations (7)

Cancer Treatment Services Arizona

Casa Grande, Arizona, United States

Long Beach Memorial Medical Center

Long Beach, California, United States

Diablo Valley Oncology Hematology

Pleasant Hill, California, United States

Little Company of Mary Hospital

Evergreen Park, Illinois, United States

Outcomes

Primary Outcomes

Local recurrence in patients treated with intra-operative electronic brachytherapy for early stage breast cancer.

Local recurrence will be assessed at one (1) month, six (6) months, one (1) year, two (2) years, three (3) years, four (4) years, and five (5) years post IORT.

Time frame: 5 Years

Occurence of serious adverse events during and following IORT treatment.

Serious adverse events are defined as a serious injury or illness that: 1. is life threatening, even if temporary in nature; 2. results in permanent impairment of a body function or permanent damage to a body structure; or 3. necessitates medical or surgical intervention to preclude permanent impairment of a body function or permanent damage to a body structure.

Time frame: 5 Years

Secondary Outcomes

Cosmesis

Cosmesis will be evaluated with the Harvard scale at one (1) month, six (6) months, and at one (1) year, two (2) years, three (3) years, four (4) years, and five (5) years post IORT.

Time frame: 5 Years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.